A tale of two insulins: Understanding basal insulin therapy in type 2 diabetes
Swinnen, S.G.H.A.

Citation for published version (APA):
Chapter

Contact frequency determines outcome of basal insulin initiation trials in type 2 diabetes

Sanne G.H.A. Swinnen and J. Hans DeVries

Diabetologia 2009;52:2324-2327
Abstract

Aims The aim of the present study was to investigate whether predetermined contact frequency with the study team and endpoint insulin dose are associated with study outcomes in basal insulin initiation trials in type 2 diabetes.

Methods A systematic Medline search was performed. Using data from the selected studies, contact frequency was plotted against HbA1c reduction and endpoint insulin dose. The importance of face-to-face vs. telephone contact was also analysed. Insulin dose was plotted against HbA1c reduction, hypoglycaemia rate and weight gain. To investigate non-specific study effects, the relationship between contact frequency and HbA1c was also assessed in dipeptidyl peptidase-4 (DPP-4) inhibitor trials.

Results The reduction in HbA1c was highly correlated with contact frequency and endpoint insulin dose ($r^2=0.751$, $p<0.001$ and $r^2=0.433$, $p=0.008$, respectively). However, after adjusting for contact frequency, the relationship between insulin dose and HbA1c reduction was no longer significant ($p=0.270$). The frequency of both clinical and telephone contacts were independent predictors of HbA1c improvement ($p=0.010$ and $p<0.001$, respectively). We found no dose-response relationship between end-of-study insulin dose and hypoglycaemia or weight gain. In DPP-4 inhibitor studies, contact frequency was not positively associated with HbA1c.

Conclusions The frequency of contact with the study team is highly correlated with the improvement in HbA1c achieved in basal insulin initiation trials in type 2 diabetic patients. This has important implications for trial design and interpretation, as well as for clinical care.
Introduction
In type 2 diabetes basal insulin preparations are advocated for the initiation of insulin therapy (1). Insulin initiation using insulin detemir (NN304) [B29Lys(e-tetradecanoyl),desB30 human insulin] or insulin glargine (A21Gly,B31Arg,B32Arg human insulin) has been examined in a number of Phase 3 and 4 clinical studies (2-8), comparing either analogue with NPH insulin or with each other (6) for their ability to decrease HbA1c levels. However, in addition to the merits of the insulin preparation under investigation, factors related to the design of the trials may affect this and other study endpoints. Therefore, we explored whether frequency of contact with the study team as per study protocol and endpoint insulin dose are associated with study outcomes in randomised controlled trials (RCTs) comparing insulin initiation with one basal insulin vs. another in insulin-naive participants with type 2 diabetes.

Methods
Medline was searched using the terms ‘detemir’, ‘glargine’, ‘neutral protamine hagedorn’, ‘NPH’, ‘neutral protamine lispro’, ‘NPL’, ‘type 2 diabetes’, ‘non-insulin dependent diabetes mellitus’ and ‘NIDDM’. In order to take the current more stringent glycaemic goals and the relatively recent use of insulin titration algorithms into account, the search was limited to studies published between April 1999 and April 2009. All English-language RCTs with a duration ≥24 weeks comparing insulin initiation with a basal insulin vs. another basal insulin in insulin-naive type 2 diabetic participants were included. Studies investigating combination therapy with rapid-acting insulin and those that had differences across treatment arms in additional glucose-lowering interventions (e.g. oral agents), titration algorithms and/or contact frequency were excluded.

The search yielded 417 papers, including 112 RCTs, of which ten met our criteria (2-11). Using these, associations between the frequency of contact as per protocol and the study outcomes reduction in HbA1c and endpoint daily insulin dose were explored by plotting the contact frequency (clinical and telephone contacts combined and standardised to the number of contacts per year) against the two outcome measures. To examine the relative importance
of clinical vs. telephone contact, we standardised both to the number of contacts per year and performed a multivariable linear regression analysis. Similarly, endpoint insulin dose, related to the study design factors titration frequency and titration target, was plotted against the study outcomes HbA1c reduction, hypoglycaemia rate and weight gain. For all associations, we performed weighted least squares regression using treatment group size as the weight variable.

Of the ten included studies, two were excluded from all analyses as they did not report contact frequency, endpoint insulin dose as units/kg/day or endpoint weight (2,11). One more study did not mention the frequency of contact (9). Three more studies did not report insulin dose as units/kg/day but for two this could be calculated (3,4). For another three studies the change in HbA1c was calculated (5,7,8). Concerning hypoglycaemia, the studies used variable definitions. We used event rates rather than numbers of participants affected to account for the effect of study duration on hypoglycaemia frequency. We defined hypoglycaemia as an event confirmed by a low glucose measurement, as this definition maximised the number of studies that could be included in the analysis (4-7,9). All in all, 15 treatment groups were analysed for the associations between contact frequency and HbA1c, dose and HbA1c, and dose and weight gain; 13 were analysed for the association between contact frequency and dose, and ten for the association between dose and hypoglycaemia.

In addition to the efficacy of the study insulin and certain features of the study design, improvements in HbA1c during trial participation may result from non-specific study effects (12,13). To investigate these non-specific study benefits, we also determined the relationship between contact frequency and HbA1c reduction in studies examining the initiation of dipeptidyl peptidase-4 (DPP-4) inhibitors. Both study populations chose to start a new intervention in the setting of a clinical trial, so presumably all were equally motivated to improve their diabetes management. However, in contrast with the continuous dose titration during the insulin trials, fixed dosages were used throughout the DPP-4 studies. We included the trials that were recently meta-analysed in a Cochrane systematic review and that compared DPP-4 inhibitor monotherapy with placebo or a single oral glucose-lowering agent (14). After
exclusion of one study because of lack of contact frequency data, we analysed 14 studies comprising 29 DPP-4 inhibitor treatment groups.

Results

Figure 1a shows that the improvement in HbA1c achieved in studies of basal insulin initiation in patients with type 2 diabetes was highly correlated with the predetermined frequency of contact with the study team ($r^2 = 0.751$, $p < 0.001$). Multivariable analysis of the standardised numbers of clinical visits and telephone contacts showed a strong association with HbA1c reduction (adjusted $r^2$ value: 0.754). Both frequencies were independent predictors of HbA1c improvement ($p = 0.010$ and $p < 0.001$ for clinical and telephone contacts, respectively). The regression equation was: HbA1c reduction = $0.282 + (0.033 \times \text{number of clinical contacts per year}) + (0.055 \times \text{number of telephone contacts per year})$. In the DPP-4 studies, however, higher contact frequency was not, and, if anything, negatively associated with greater improvement in glycaemic control ($r^2 = 0.233$, standardised $\beta = -0.483$, $p = 0.008$) (Fig. 1f).

In the insulin trials, we also found significant relationships between contact frequency and insulin dose at study endpoint ($r^2 = 0.366$, $p = 0.028$) (Fig. 1b), and between endpoint insulin dose and HbA1c reduction ($r^2 = 0.433$, $p = 0.008$) (Fig. 1c). The effect of increasing insulin doses on the occurrence of hypoglycaemia was not apparent in insulin-naive patients ($r^2 = 0.011$, $p = 0.774$), and we found no evidence for a dose-response relationship between insulin dose and weight gain ($r^2 = 0.076$, $p = 0.320$) (Fig. 1d and e). Finally, to determine whether contact frequency and insulin dose were also independently associated with improvement in glycaemic control, we performed a multivariable regression analysis. The adjusted $r^2$ value of this model was 0.718, and while contact frequency remained an independent predictor of HbA1c reduction ($p = 0.003$), insulin dose did not ($p = 0.270$).
Figure 1 Relationships between (a) the frequency of contact with the study team as per study protocol and mean reduction in HbA1c level (15 treatment groups, $r^2=0.751$, standardised $\beta=0.866$, $p<0.001$), and (b) the frequency of contact and mean end-of-study daily insulin dose (13 treatment groups, $r^2=0.366$, standardised $\beta=0.605$, $p=0.028$). Relationships between mean endpoint daily insulin dose and (c) mean reduction in HbA1c level (15 treatment groups, $r^2=0.433$, standardised $\beta=0.658$, $p=0.008$), (d) rate of hypoglycaemia confirmed by a low glucose measurement per patient-year (ten treatment groups, $r^2=0.011$, standardised $\beta=-0.104$, $p=0.774$) and (e) mean weight gain (15 treatment groups, $r^2=0.076$, standardised $\beta=-0.276$, $p=0.320$). RCTs comparing insulin initiation with a basal insulin vs. another basal insulin in insulin-naive participants with type 2 diabetes were analysed. f Relationship between the predetermined frequency of contact and mean reduction in HbA1c level in clinical studies investigating initiation of DPP-4 inhibitor treatment (29 treatment groups, $r^2=0.233$, standardised $\beta=-0.483$, $p=0.008$). The size of the symbols reflects treatment group size.

Discussion

Our main finding was that, while there were significant dose-response relationships between the predetermined frequency of contact and endpoint insulin dose and the improvement in glycaemic control achieved during RCTs investigating basal insulin initiation in type 2 diabetic patients, only contact frequency was an independent predictor of HbA1c reduction. The frequency of both clinical visits and telephone contacts showed a significant relationship with HbA1c improvement, but a higher frequency of telephone contact may be particularly beneficial. In studies examining the start of DPP-4 inhibitors we did not find a positive association between contact frequency and HbA1c improvement.

Assuming that the non-specific study effects of the insulin and DPP-4 trials were comparable, the lack of a logical association between contact frequency and HbA1c improvement in the latter studies suggests that the benefit of frequent patient contact found in the insulin trials is primarily related to the frequency of insulin dose titration. This is supported not only by Fig. 1b, which shows a significant relationship between contact frequency and insulin doses used at study endpoint, but also by the multivariable analysis of the frequencies of clinical and telephone contacts. The higher $\beta$ coefficient for telephone contacts suggests that these may be more beneficial than clinical visits, presumably due to their focus on dose titration (compared with the performance of many study-related procedures during clinical visits).

However, it cannot be ruled out that the non-specific study benefits did indeed differ between the two types of trials. In type 1 diabetes, the improvement in glycaemic control after trial participation itself was found to be mediated
by increased self-monitoring of blood glucose (SMBG) and a more active coping style (13). In contrast with the insulin initiation trials, SMBG was not performed in the DPP-4 studies. Additionally, it is possible that patients failing on oral therapy and requiring insulin are more ‘ready for change’ and more motivated to do well than those (merely) starting on another tablet. However, regardless of whether the benefit of regular patient contact is primarily related to titration frequency or to non-specific study effects, our analyses demonstrate that predetermined contact frequency is a major determinant of the HbA1c improvement achieved in insulin initiation trials. In addition to the obvious consequences for the design and interpretation of clinical trials comparing different insulin preparations, our findings have important implications for patient care, in as far as providing frequent contact after starting insulin therapy may be very effective in improving glycaemic control.

We found no relationship between daily insulin dose and hypoglycaemia event rate, but this may reflect the low a priori risk of hypoglycaemia of the study populations. These type 2 diabetic participants had just started insulin treatment, so were presumably protected against hypoglycaemia by residual endogenous insulin secretion. An alternative possible explanation for the observed lack of a relationship is that participants on higher daily doses after titration have similar rates of hypoglycaemia to those in whom titration is stopped at lower insulin doses. In this case, the graph could suggest that perceived risk of hypoglycaemia is the signal to stop insulin dose titration. The lack of association between insulin dose and weight gain suggests that the weight increase commonly seen after initiation of insulin therapy is related to reductions in glucosuria and/or increased energy intake, rather than to the number of insulin injections or the daily insulin dose (15).

In conclusion, the frequency of contact with the study team is highly correlated with the improvement in glycaemic control achieved after basal insulin initiation in type 2 diabetes. Our analyses indicate that when comparing the outcomes of different clinical trials, their design should also be considered. Our findings also have implications for trial design and patient care. Frequent contact and dose titration may facilitate successful insulin initiation.
Duality of interest
Sanne G.H.A. Swinnen is employed by the Department of Internal Medicine of the Academic Medical Centre, Amsterdam, the Netherlands, partly through funding from Novo Nordisk and sanofi-aventis for the conduct of clinical trials. J. Hans DeVries has received honoraria for consultancy work as well as research funding from Novo Nordisk and sanofi-aventis.
References


